Zenni EYEWEAR

Bass Pro Shops

How an Unproven Alzheimer’s Drug Got Approved


By BY PAM BELLUCK, SHEILA KAPLAN AND REBECCA ROBBINS
Health
https://ift.tt/2V2fsC8
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
New York Times
Aduhelm (Drug), Alzheimer's Disease, Drugs (Pharmaceuticals), Labeling and Labels (Product), Clinical Trials, Elderly, Science and Technology, Regulation and Deregulation of Industry, Research, Brain, your-feed-science, your-feed-healthcare
July 20, 2021 at 02:12AM

H&R Block

Popular posts from this blog

Why Do We Think It's Okay to Invade Strangers' Privacy?